시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 성장 호르몬 결핍증 시장 보고서(2025년)
Growth Hormone Deficiency Global Market Report 2025
상품코드 : 1720806
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,546,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,462,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,378,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

성장 호르몬 결핍증 시장 규모는 앞으로 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 5.9%로 성장할 것으로 예상되며, 54억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 유전성 질환의 유병률 증가, 전략적 이니셔티브 증가, 연구개발 노력 강화, Gh 질환 이환율 증가, 임상검사수 확대로 인한 것으로 보입니다. 예측 기간의 주요 동향으로는 기술의 진보, 치료 선택의 확대, 진단 기술의 개선, 최근의 동향, 생명 공학의 진보 등을 들 수 있습니다.

유전성 질환의 유병률 증가는 성장 호르몬 결핍증 시장의 확대를 이끌 것으로 예측됩니다. 유전성 질환은 개인의 DNA의 이상이나 돌연변이에 기인하는 병리학이며, 유전성 또는 자연 발생 중 어느 하나입니다. 진단기술의 진보, 인지도의 향상, 임산부 연령의 상승, 돌연변이를 일으키는 환경 요인, 인구 증가, 이환 환자의 생존율의 향상 등, 여러 요인이 만연율의 상승에 기여하고 있습니다. 성장 호르몬 결핍증 치료는 특정 유전 질환과 관련된 성장 관련 합병증을 관리하는 데 도움이 됩니다. 예를 들어 2022년 12월 영국 정부부문인 보건사회의학부(DHSC)가 발표한 보고서에 따르면 2022년 10월에는 약 3만 3,000개의 총 유전체 상당한 서열이 결정되어 평균 진단 수율은 32%로, 특정 질환에서는 61%로 상승했습니다. 그 결과, 유전성 질환의 유병률 증가가 성장 호르몬 결핍증 시장의 성장에 박차를 가하고 있습니다.

성장 호르몬 결핍증 시장의 주요 기업은 소아 성장 호르몬 결핍증(GHD)에 대한 비변형 소마트로핀과 같은 혁신적인 치료의 개척에 주력하고 있습니다. 사용되는 성장 호르몬과 같지만, 스카이트로파로 주 1회 투여할 수 있도록 제제화된 것입니다. Pharma A/S는 소아 GHD의 주 1회 치료로서 SKYTROFA(lonapegsomatropin)를 발매했습니다. 호르몬 연일 투여 요법에 비해 치료 성적이 향상될 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

SHW
영문 목차

영문목차

Growth hormone deficiency (GHD) is a medical condition in which the pituitary gland does not produce enough growth hormone (GH). This deficiency leads to stunted growth and development in children and various metabolic issues in adults. Growth hormone deficiency can be congenital (present at birth) or acquired due to injury, tumors, infections, or other medical conditions affecting the pituitary gland.

The primary types of growth hormone deficiency are pediatric growth hormone deficiency and adult growth hormone deficiency. Pediatric growth hormone deficiency focuses on children with inadequate growth hormone production, resulting in stunted growth and delayed development. Treatments involved are pharmacological therapy, recombinant human growth hormone, human pituitary gland extracts, and surgery. The various routes of administration include intravenous, intramuscular, and others. They are distributed through several channels, such as hospital pharmacy, online pharmacy, and retail pharmacy, and are used by multiple end users, including hospitals, home care, specialty clinics, and others.

The growth hormone deficiency market research report is one of a series of new reports from The Business Research Company that provides growth hormone deficiency market statistics, including the growth hormone deficiency industry global market size, regional shares, competitors with the growth hormone deficiency market share, detailed growth hormone deficiency market segments, market trends, and opportunities, and any further data you may need to thrive in the growth hormone deficiency industry. This growth hormone deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth hormone deficiency market size has grown strongly in recent years. It will grow from $4.06 billion in 2024 to $4.31 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to the rising number of strategic initiatives, increasing incidences of brain tumors, growing demand for hormone therapies, increased elderly population, and rising government funding for healthcare.

The growth hormone deficiency market size is expected to see strong growth in the next few years. It will grow to $5.42 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth during the forecast period can be attributed to the increasing prevalence of genetic disorders, the rising number of strategic initiatives, enhanced research and development efforts, the growing morbidity of Gh disease, and the expanding number of clinical trials. Key trends in the forecast period include technological advancements, the expansion of treatment options, improvements in diagnostic techniques, recent developments, and progress in biotechnology.

The increasing prevalence of genetic disorders is expected to drive the expansion of the growth hormone deficiency market. Genetic disorders are medical conditions resulting from abnormalities or mutations in an individual's DNA, either inherited or occurring spontaneously. Several factors contribute to their rising prevalence, including advancements in diagnostic technology, increased awareness, rising maternal age, environmental factors causing mutations, population growth, and improved survival rates for affected individuals. Growth hormone deficiency treatments help manage growth-related complications associated with certain genetic conditions. For instance, according to a report published in December 2022 by the Department of Health & Social Care (DHSC), a UK-based government department, approximately 33,000 whole genome equivalents were sequenced in October 2022, with an average diagnostic yield of 32%, rising to 61% in specific conditions. As a result, the increasing prevalence of genetic disorders is fueling the growth of the growth hormone deficiency market.

Leading companies in the growth hormone deficiency market are focusing on developing innovative treatments, such as unmodified somatropin, for pediatric growth hormone deficiency (GHD). Unmodified somatropin is the same growth hormone used in daily GHD treatments but formulated for once-weekly administration with Skytrofa. For example, in September 2023, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, launched SKYTROFA (lonapegsomatropin) as a once-weekly treatment for pediatric GHD. This innovation enhances convenience, improves adherence, and offers potentially better treatment outcomes compared to traditional daily growth hormone therapies. As the first and only FDA-approved once-weekly treatment for pediatric GHD, it represents a significant advancement in endocrinology and pediatric care.

In February 2022, Pfizer Inc., a US-based pharmaceutical company, partnered with OPKO Health Inc. to advance the treatment of pediatric growth hormone deficiency (GHD). Through this collaboration, Pfizer and OPKO Health aim to develop and commercialize NGENLA (somatrogon), a next-generation long-acting recombinant human growth hormone that reduces the injection frequency from once daily to once weekly. This approach improves treatment adherence, minimizes the burden of disease management, and enhances the overall quality of life for children and adolescents with GHD. OPKO Health Inc. is a US-based company specializing in the development and commercialization of treatments for growth hormone deficiency.

Major players in the growth hormone deficiency market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Genentech Inc., Ipsen Biopharmaceuticals Inc., Opko Health Inc., JCR Pharmaceuticals Co. Ltd., Ferring Pharmaceuticals Inc., Ascendis Pharma A/S, Rani Therapeutics Inc., AnkeBio Co. Ltd., Aeterna Zentaris Inc., Zhongshan Sinobioway Hygene Biomedicine Co. Ltd., Versartis Inc., I-Mab Biopharma Co. Ltd.

North America was the largest region in the growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in growth hormone deficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the growth hormone deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The growth hormone deficiency market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and specialized services. The market value includes the value of related goods sold by the service provider or included within the service offering. The growth hormone deficiency market consists of sales of recombinant human growth hormones, long-acting growth hormones and combination therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Growth Hormone Deficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on growth hormone deficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for growth hormone deficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The growth hormone deficiency market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Growth Hormone Deficiency Market Characteristics

3. Growth Hormone Deficiency Market Trends And Strategies

4. Growth Hormone Deficiency Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Growth Hormone Deficiency Growth Analysis And Strategic Analysis Framework

6. Growth Hormone Deficiency Market Segmentation

7. Growth Hormone Deficiency Market Regional And Country Analysis

8. Asia-Pacific Growth Hormone Deficiency Market

9. China Growth Hormone Deficiency Market

10. India Growth Hormone Deficiency Market

11. Japan Growth Hormone Deficiency Market

12. Australia Growth Hormone Deficiency Market

13. Indonesia Growth Hormone Deficiency Market

14. South Korea Growth Hormone Deficiency Market

15. Western Europe Growth Hormone Deficiency Market

16. UK Growth Hormone Deficiency Market

17. Germany Growth Hormone Deficiency Market

18. France Growth Hormone Deficiency Market

19. Italy Growth Hormone Deficiency Market

20. Spain Growth Hormone Deficiency Market

21. Eastern Europe Growth Hormone Deficiency Market

22. Russia Growth Hormone Deficiency Market

23. North America Growth Hormone Deficiency Market

24. USA Growth Hormone Deficiency Market

25. Canada Growth Hormone Deficiency Market

26. South America Growth Hormone Deficiency Market

27. Brazil Growth Hormone Deficiency Market

28. Middle East Growth Hormone Deficiency Market

29. Africa Growth Hormone Deficiency Market

30. Growth Hormone Deficiency Market Competitive Landscape And Company Profiles

31. Growth Hormone Deficiency Market Other Major And Innovative Companies

32. Global Growth Hormone Deficiency Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Growth Hormone Deficiency Market

34. Recent Developments In The Growth Hormone Deficiency Market

35. Growth Hormone Deficiency Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기